Patent estate

RADIUS — Patent Portfolio

1 drug with active patents · 9 active patents · 0 expired · 0 biologics with BPCIA exclusivity

AI-enriched 9/9 patents with grounded plain-English summaries · sourced from FDA Orange Book + Purple Book · updated 2026-05-18

§
Strategic Patent Estate Brief
AI-grounded executive summary · generated 2026-05-16

Verdict The RADIUS portfolio is moderately strong with a significant cliff year in 2027 and no revenue at risk in the next 5 years.

Portfolio overview The RADIUS portfolio consists of a total of 1 drug with patents, with 9 active US patents and 0 expired US patents. The average vulnerability score is 65, indicating a moderate level of vulnerability. The portfolio has 0 ironclad patents and 5 vulnerable patents. There are no biologics in the portfolio.

Cliff calendar In 2027, 1 drug will lose exclusivity, including Tymlos. This marks a significant cliff year for the company.

Most exposed drugs The top drug facing near-term loss of exclusivity is Tymlos, with an earliest active patent expiry date of 2027-10-03, an average vulnerability score of 65, and no annual revenue data available. This drug has 9 patents and is a significant contributor to the company's portfolio.

Biologic exclusivity There are no biologics in the RADIUS portfolio, and therefore, there is no BPCIA 12-year reference product exclusivity to consider.

Strategic implications The RADIUS portfolio has no revenue at risk in the next 5 years. However, the company should consider lifecycle moves to maintain its competitive position, such as subQ switches, label extensions, or combination filings, to maximize the value of its portfolio.

Sources: FDA Orange Book · FDA Purple Book · INPADOC family · USPTO · vulnerability scoring. Not legal advice.

Loss of exclusivity calendar · next 12 years

Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.

1 2027 1 2031 1 2038

Patent estate by drug

Tymlos (ABALOPARATIDE)

Cliff 2027 · 1y
Method of Use 6 Formulation 3
  • USRE49444 Vuln 76 2031-04-28
    This patent, US RE49444, protects a specific method of using the drug Tymlos.
  • US8748382 Vuln 75 2027-10-03
    This patent protects a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) for treating osteoporosis or increasing bone mass or quality.
  • US11782041 Vuln 70 2038-04-30
    This patent protects methods of analyzing, storing, and using abaloparatide, specifically in relation to its newly discovered isomers.
See all 9 patents →

Patent classification breakdown · active patents

By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.

  • Method of Use 6 patents
  • Formulation 3 patents

Sources

  • FDA Orange Book — small-molecule patents listed against approved NDAs.
  • FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
  • USPTO Patent Public Search — title, abstract, claim text grounding.
  • AI summaries generated by Drug Landscape, grounded in source claim text.

Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.

Track RADIUS's patent estate

Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.

↓ CSV export